Fate Therapeutics, Inc.
US ˙ NasdaqGM ˙ US31189P1021

SecurityFATE / Fate Therapeutics, Inc.
InstitutionInvesco Ltd.
Latest Disclosed Ownership375,886 shares
Latest Disclosed Value $ 451,063
Invesco Ltd. reports 0.83% decrease in ownership of FATE / Fate Therapeutics, Inc.

On May 12, 2026 - Invesco Ltd. filed a 13F-HR form disclosing ownership of 375,886 shares of Fate Therapeutics, Inc. (US:FATE) valued at $451,063 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 19, 2026 disclosing 379,025 shares of Fate Therapeutics, Inc.. This represents a change in shares of -0.83% during the quarter. The current value of the position is $744,254 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F FATE THERAPEUTICS COM 31189P102 375,886 -3,139 -0.83 451 21.24 0.0001
2026-02-19 2025-12-31 13F FATE THERAPEUTICS COM 31189P102 379,025 64,200 20.39 372 -6.06 0.0001
2025-11-13 2025-09-30 13F FATE THERAPEUTICS COM 31189P102 314,825 59,453 23.28 397 38.46 0.0001
2025-08-13 2025-06-30 13F FATE THERAPEUTICS COM 31189P102 255,372 41,869 19.61 286 70.24 0.0000
2025-05-12 2025-03-31 13F FATE THERAPEUTICS COM 31189P102 213,503 104,569 95.99 169 -6.15 0.0000
2025-02-13 2024-12-31 13F FATE THERAPEUTICS COM 31189P102 108,934 7,056 6.93 180 -49.72 0.0000
2024-11-12 2024-09-30 13F FATE THERAPEUTICS COM 31189P102 101,878 -218 -0.21 357 6.59 0.0001
2024-08-13 2024-06-30 13F FATE THERAPEUTICS COM 31189P102 102,096 -863,335 -89.42 335 -95.29 0.0001
2024-05-14 2024-03-31 13F FATE THERAPEUTICS COM 31189P102 965,431 835,977 645.77 7,086 1,364.05 0.0015
2024-02-13 2023-12-31 13F FATE THERAPEUTICS COM 31189P102 129,454 3,867 3.08 484 81.95 0.0001
2023-11-13 2023-09-30 13F FATE THERAPEUTICS COM 31189P102 125,587 6,791 5.72 266 -52.92 0.0001
2023-08-11 2023-06-30 13F FATE THERAPEUTICS COM 31189P102 118,796 -4,465 -3.62 565 -19.52 0.0001
2023-05-12 2023-03-31 13F FATE THERAPEUTICS COM 31189P102 123,261 75,782 159.61 703 46.56 0.0002
2023-02-13 2022-12-31 13F FATE THERAPEUTICS COM 31189P102 47,479 -3,687 -7.21 479 -58.20 0.0001
2022-11-14 2022-09-30 13F FATE THERAPEUTICS COM 31189P102 51,166 3,616 7.60 1,146 -2.80 0.0004
2022-08-15 2022-06-30 13F FATE THERAPEUTICS COM 31189P102 47,550 -967,567 -95.32 1,179 -97.00 0.0004
2022-05-16 2022-03-31 13F FATE THERAPEUTICS COM 31189P102 1,015,117 131,838 14.93 39,356 -23.85 0.0100
2022-02-14 2021-12-31 13F FATE THERAPEUTICS COM 31189P102 883,279 762,832 633.33 51,680 623.91 0.0125
2021-11-15 2021-09-30 13F FATE THERAPEUTICS COM 31189P102 120,447 -763,687 -86.38 7,139 -90.70 0.0018
2021-08-17 2021-06-30 13F FATE THERAPEUTICS COM 31189P102 884,134 206,998 30.57 76,734 37.44 0.0189
2021-05-17 2021-03-31 13F FATE THERAPEUTICS COM 31189P102 677,136 253,280 59.76 55,831 44.86 0.0149
2021-02-16 2020-12-31 13F FATE THERAPEUTICS COM 31189P102 423,856 102,309 31.82 38,541 199.86 0.0112
2020-11-16 2020-09-30 13F FATE THERAPEUTICS COM 31189P102 321,547 296,773 1,197.92 12,853 1,412.12 0.0043
2020-08-14 2020-06-30 13F FATE THERAPEUTICS COM 31189P102 24,774 -122,688 -83.20 850 -74.05 0.0003
2020-05-15 2020-03-31 13F FATE THERAPEUTICS COM 31189P102 147,462 147,462 3,275 0.0014
2019-11-14 2019-09-30 13F FATE THERAPEUTICS COM 31189P102 0 -50,107 -100.00 0 -100.00
2019-08-14 2019-06-30 13F/A-1 FATE THERAPEUTICS COM 31189P102 50,107 -3,072 -5.78 1,017 8.89 0.0003
2019-08-14 2019-06-30 13F FATE THERAPEUTICS COM 31189P102 50,107 -3,072 1,017
2019-05-15 2019-03-31 13F FATE THERAPEUTICS COM 31189P102 53,179 -17,683 -24.95 934 2.75 0.0003
2019-02-14 2018-12-31 13F FATE THERAPEUTICS COM 31189P102 70,862 -515,916 -87.92 909 -90.49 0.0003
2018-11-14 2018-09-30 13F FATE THERAPEUTICS COM 31189P102 586,778 404,542 221.99 9,559 362.46 0.0030
2018-08-14 2018-06-30 13F FATE THERAPEUTICS COM 31189P102 182,236 182,236 2,067 0.0007
2017-11-14 2017-09-30 13F FATE THERAPEUTICS COM 31189P102 0 -20,736 -100.00 0 -100.00
2017-08-14 2017-06-30 13F FATE THERAPEUTICS COM 31189P102 20,736 8,271 66.35 67 17.54 0.0000
2017-05-15 2017-03-31 13F FATE THERAPEUTICS COM 31189P102 12,465 12,465 57 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.